[111in]in-dota-tco-trastuzumab
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 10, 2025 (NCT07009184)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Radiopharmaceutical
ERBB2 radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07009184 | Early Phase 1 (Phase 1) | Dec 10, 2025 | Radboud University, Tagworks Pharmaceuticals BV |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Tagworks Pharmaceuticals BV | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1